Coherus BioSciences Inc (NAS:CHRS)
$ 1.78 0.02 (1.14%) Market Cap: 204.21 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 06:35PM GMT
Release Date Price: $12.54 (+3.98%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Good afternoon, everyone. My name is Balaji Prasad. I lead the specialty pharmaceuticals coverage for Barclays. And continuing on our spec pharma track for the afternoon, I'm delighted to present the entire management team of Coherus here. So we have Denny Lanfear, CEO; Paul Reider, Chief Commercial Officer; and McDavid Stilwell, CFO; and Theresa LaVallee, Chief Development Officer.

Denny and team, thank you for taking your time to join us this afternoon.

Questions & Answers

Balaji V. Prasad;Dennis M. Lanfear<
Barclays Bank PLC, Research Division - Director

So let's dive right into the questions. It's been around a year since you announced your shift to biologics and kind of a strategic shift away from biosimilars, at least no further investment in biosimilars. So as you look at the journey you have passed over the past 1 year, how successful do you think this strategy has been? And what could have been better? Are you happy with your progress as of now?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot